Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle

Journal of Biomedical Nanotechnology

Volumn 6, Issue 2, 2010, Pages 153-157

  Liu, Xinrong ^a   Nakamura, Kayoko ^b   Wang, Yi ^c   Cheng, Dengfeng ^a   Liang, Minmin ^a   Xiao, Nan ^a   Chen, Ling ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Japan Radioisotope Association   (Japan)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Antisense oligomer; Auger electron; Her2; Nanoparticle; Radiotherapy

Indexed keywords

ANTISENSE; ANTISENSE OLIGOMER; AUGER ELECTRON; AUGER ELECTRON EMITTERS; CANCER CELLS; CLONOGENIC SURVIVAL ASSAYS; DOSE-ESCALATION STUDY; HER2; HUMAN BREAST CANCER CELLS; STREPTAVIDIN; SURVIVING FRACTIONS; THERAPEUTIC DOSE; THREE-COMPONENT; TRASTUZUMAB; TUMOR CELLS;

AUGER ELECTRON SPECTROSCOPY; AUGERS; CELLS; CYTOTOXICITY; MONOCLONAL ANTIBODIES; NANOPARTICLES; PEPTIDES; RADIOTHERAPY;

CELL CULTURE;

CYCLIC AMP DEPENDENT PROTEIN KINASE; GLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLARGININE; IODINE 125; NANOPARTICLE; PEPTIDE; PHOSPHORODIAMIDATE MORPHOLINO; PROTEIN; STREPTAVIDIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL CULTURE; NUCLEOTIDE SEQUENCE; RADIOACTIVITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, GEL; CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MORPHOLINES; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; STREPTAVIDIN; TUMOR STEM CELL ASSAY;

EID: 77955453191     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1111     Document Type: Article

References (24)

1. Y. Wang, K. Nakamura, X. Liu, N. Kitamura, A. Kubo, and D. J. Hnatowich, Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture. Bioconj. Chem. 18, 1338 (2007).
2. Y. Wang, X. Liu, K. Nakamura, L. Chen, M. Rusckowski, and D. J. Hnatowich, In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles. Cancer Biother. Radiopharm. 24, 573 (2009).
3. Y. M. Zhang, Y. Wang, N. Liu, Z. H. Zhu, M. Rusckowski, and D. J. Hnatowich, In vitro investigations of tumor targeting with 99mTc-labeled antisense DNA. J. Nucl. Med. 42, 1660 (2001).
4. Y. S. Cho-Chung, Antisense protein kinase A RI alpha-induced tumor reversion: Portrait of a microarray. Biochim. Biophys. Acta. 1697, 71 (2004).
5. Y. Zhang, C. Liu, N. Liu, G. Flores Ferro, M. Rusckowski, and D. J. Hnatowich, Electrostatic binding with tat and other cationic peptides increases cell accumulation of 99mTc-antisense DNAs without entrapment. Mol. Imaging Biol. 5, 240 (2003).
6. B. Albarran, R. To, and P. S. Stayton, A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells. Protein Eng. Des. Sel. 18, 147 (2005).
7. X. Liu, Y. Wang, K. Nakamura, S. Kawauchi, A. Akalin, D. Cheng, L. Chen, M. Rusckowski, and D. J. Hnatowich, Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In. J. Nucl. Med. 50, 582 (2009).
8. X. Liu, Y. Wang, K. Nakamura, A. Kubo, and D. J. Hnatowich, Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery. Cancer Gene Ther. 15, 126 (2008).
9. Y. Wang, X. Liu, L. Chen, D. Cheng, M. Rusckowski, and D. J. Hnatowich, Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. Eur. J. Nucl. Med. Mol. Imaging 36, 1977 (2009),
10. R. W. Howell, Auger processes in the 21st century. Int. J. Radiat. Biol. 84, 959 (2008).
11. L. Bodei, A. I. Kassis, S. J. Adelstein, and G. Mariani, Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: Experimental models and clinical applications. Cancer Biother. Radiopharm. 18, 861 (2003).
12. L. A. Khawli and A. I. Kassis, Synthesis of 125I labeled N-succinimidyl p-iodobenzoate for use in radiolabeling antibodies. Nucl. Med. Biol. 16, 727 (1989).
13. H. Dougan, J. B. Hobbs, J. I. Weitz, and D. M. Lyster, Synthesis and radioiodination of a stannyl oligodeoxyribonucleotide. Nucl. Acid Res. 25, 2897 (1997).
14. W. D. Bloomer and S. J. Adelstein, Letter: Antineoplastic effect of iodine-125-labelled iododeoxyuridine. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 27, 509 (1975).
15. X. Sun, T. Chu, X. Liu, and X. Wang, t-Butyloxycarbonyl: An ordinary but promising group for protecting peptides from deiodination. Appl. Radiat. Isot. 64, 645 (2006).
16. K. Nakamura, Y. Wang, X. Liu, N. Kitamura, A. Kubo, and D. J. Hnatowich, Cell culture and xenografted animal studies of radiolabeled antisense DNA/carrier nanoparticles using streptavidin as linker. J. Nucl. Med. 48, 1845 (2007).
17. X. Liu, Y. Wang, K. Nakamura, G. Liu, S. Dou, M. Rusckowski, and D. J. Hnatowich, Cytoplasmic and nuclear accumulation of antisense oligomers incubated as streptavidin delivery nanoparticles. Curr. Radiopharmaceuticals 2, 112 (2009).
18. X. Liu, K. Nakamura, Y. Wang, Y. Wang, G. Liu, J. He, H. Ding, P. Lu, M. Rusckowski, A. Kubo, and D. J. Hnatowich, Initial mechanistic studies of antisense targeting in cells. J. Nucl. Med 47, 360 (2006).
19. F. Buchegger, F. Perillo-Adamer, Y. M. Dupertuis, and A. B. Delaloye, Auger radiation targeted into DNA: A therapy perspective. Eur. J. Nucl. Med. Mol. Imaging 33, 1352 (2006).
20. M. Faraggi, I. Gardin, C. de Labriolle-Vaylet, J. L. Moretti, and B. D. Bok, The influence of tracer localization on the electron dose rate delivered to the cell nucleus. J. Nucl. Med. 35, 113 (1994).
21. P. Unak, Targeted Tumor Radiotherapy. Braz. arch. biol. Technol. 45, 97 (2002).
22. T. Faltus, J. Yuan, B. Zimmer, A. Krämer, S. Loibl, M. Kaufmann, and K. Strebhardt, Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neuoverexpressing breast cancer cells. Neoplasia. 6, 786 (2004).
23. E. A. Lee, M. K. Keutmann, M. L. Dowling, E. Harris, G. Chan, and G. D. Kao, Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol. Cancer Ther. 3, 661 (2004).
24. A. C. Steffen, L. Göstring, V. Tolmachev, S. Palm, B. Stenerlöw, and J. Carlsson, Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur. J. Nucl. Med. Mol. Imaging 35, 1179 (2008).